Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical vancomycin for prevention of sternal wound infection after open heart surgery
IRCT20200328046886N7Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Dec 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of vancomycin in surgical site infection (SSI) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Number of sternal wound infections within 2 weeks after surgery and Number of sternal wound infections within 2 months after surgery. Started Dec 2024; status: completed.
02
Drugs
vancomycin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on IRCT20200328046886N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200328046886N7.